SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
May 9, 2019
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
(Commission File Number)
(IRS Employer Identification No.)
2505 Meridian Parkway, Suite 100
(Address of principal executive offices)
Registrant’s telephone number, including area code: (919) 806-1074
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange on which registered
Common Stock, par value $0.001 per share
The Nasdaq Global Market
Item 2.02 Results of Operations and Financial Condition.
On May 9, 2019, we announced our financial results for the first quarter ended March 31, 2019 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information in this Item 2.02 and the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and the attached Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.
Financial Statements and Exhibits.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: May 9, 2019
/s/ Timothy W. Trost
Timothy W. Trost
Senior Vice President, Chief Financial Officer and Corporate Secretary
Chimerix Announces First Quarter 2019 Financial Results and Strategy Update
- Reports Positive Top-line Survival Data from Pivotal Mouse Study as Key Milestone on Path to Smallpox Regulatory Submission -
- Plan to Focus on Execution of Smallpox Program, Halting All Other Brincidofovir Development Activities -
- Restructuring to Reduce Workforce by More Than 50%, Maintaining Key Capabilities and Preserving Capital for New Programs -
- Conference Call at 8:30 a.m. ET Today -
DURHAM, N.C., May 9, 2019 -- Chimerix (NASDAQ:CMRX), today reported financial results for the first quarter ended March 31, 2019 and provided an update on corporate strategy. Chimerix announced positive top-line results from the in-life portion of the mousepox study with ectromelia virus (ECTV), the Company’s second animal model under the Food and Drug Administration (FDA) Animal Efficacy Rule. In addition, Chimerix announced the discontinuation of all ongoing human clinical trials for oral and intravenous brincidofovir (BCV) due to low patient accrual across all active trials. Reflecting these developments, Chimerix plans to undertake a corporate restructuring, including a greater than 50% reduction in staff. The Company intends to pursue external opportunities to build its pipeline of product candidates.
“We’re very pleased to now have shown significant improvements in survival, the primary endpoint in both the rabbitpox and mousepox animal models. This is a key milestone on the path toward an anticipated 2020 New Drug Application (NDA) of oral BCV as a medical countermeasure for smallpox and the potential for associated non-dilutive capital,” stated Mike Sherman, Chief Executive Officer of Chimerix. “We are committed to pursuing programs where we can quickly address unmet patient needs with a meaningful benefit. Following an objective assessment of all internal activities, we will focus resources on the execution of the smallpox program as we identify additional attractive opportunities to create value for patients and shareholders. Our decisiveness here is a reflection of our determination to create value and help patients.
The decision to reduce staff following these strategic decisions was a difficult but necessary action. We are thankful for the commitment of these talented employees who have contributed so much to the Company. We will be working closely with those affected by the restructuring to support them in this transition,” added Mr. Sherman.
The Company plans to make the existing clinical supply of BCV available to patients as part of the expanded access program.
First Quarter and Recent Highlights
BCV for Smallpox
Today, Chimerix announced positive top-line results from the in-life portion of the ECTV study, which examined BCV using the Company’s second animal model of human smallpox conducted under the Animal Efficacy Rule. Chimerix is collaborating with the Biomedical Advanced Research and
Development Authority (BARDA) for the development of BCV as a potential medical countermeasure for smallpox.
The study was a randomized, blinded, placebo-controlled, parallel-group study to evaluate the efficacy of two different BCV dosing regimens versus a placebo (PBO) control group in mice infected with the mousepox virus. Mice were randomized to one of the following BCV treatment groups or placebo:
A BCV dose regimen of 20/5/5 mg/kg administered at 48-hour intervals with treatment initiation on post-infection days 4, 5, 6 or 7; or
A BCV dose regimen of 10/5/5 mg/kg administered at 48-hour intervals with treatment initiation on post-infection days 4, 5 or 6.
Initiation Post Infection
P value vs PBO
BCV Dose Regimen
27 / 32 (84%)
24 / 32 (75%)
15 / 32 (47%)
12 / 32 (38%)
10/5/5 BCV Dose Regimen
25 / 32 (78%)
21 / 32 (66%)
11 / 32 (34%)
4 / 32 (13%)
As shown above, all BCV treatment groups demonstrated a statistically significant survival benefit compared with placebo regardless of treatment initiation day. Survival was highest in both treatment groups where BCV was administered on Day 4, with the 20/5/5 mg/kg treatment regimen showing 84% survival and the 10/5/5 regimen showing 78% survival. Survival in the placebo group was 13%. The median time to death in animals receiving placebo was 8.5 days after infection, indicating that BCV treatment was effective at preventing mortality from mousepox virus even when treatment was initiated well past the midpoint of disease.
Data from this mousepox study and the Company’s rabbitpox studies are intended to address the requirement under the FDA’s Animal Efficacy Rule for two different animal models of efficacy. Further confirmatory analyses (e.g., secondary endpoints) of these studies are currently underway.
Contingent upon receiving final audited results of these two key animal efficacy studies, along with preparing data necessary to bridge to a recommended human dose, Chimerix intends to submit marketing applications for BCV for the treatment of smallpox in 2020.
Management and Corporate Updates
In April, Chimerix appointed Mike Sherman, former Chief Executive Officer of Endocyte, Inc., as Chief Executive Officer and Mike Andriole, former Chief Financial Officer of Endocyte, Inc., as the newly created Chief Business Officer.
As a result of the restructuring described above, the Company will incur a restructuring related charge in the second quarter of 2019.
First Quarter 2019 Financial Results
Chimerix reported a net loss of $17.7 million, or $0.35 per basic and diluted share, for the first quarter of 2019. During the same period in 2018, Chimerix recorded a net loss of $19.8 million, or $0.42 per basic and diluted share.
Revenues for the first quarter of 2019 increased to $2.4 million, compared to $0.8 million for the same period in 2018.
Research and development expenses decreased to $13.5 million for the first quarter of 2019, compared to $14.4 million for the same period in 2018.
General and administrative expenses increased to $7.7 million for the first quarter of 2019, compared to $6.7 million for the same period in 2018.
Loss from operations was $18.8 million for the first quarter of 2019, compared to a loss from operations of $20.3 million for the same period in 2018.
Chimerix's balance sheet at March 31, 2019 included $171.6 million of capital available to fund operations, no debt, and approximately 51.0 million outstanding shares of common stock. Chimerix currently expects to end 2019 with approximately $140 million in capital to fund operations which will reflect payments related to the close-out of the oral and intravenous clinical trials and severance costs from the restructuring described above.
Conference Call and Webcast
Chimerix will host a conference call and live audio webcast to discuss first quarter 2019 results and the Company's strategic update today at 8:30 a.m. ET. To access the live conference call, please dial 877-354-4056 (domestic) or 678-809-1043 (international) at least five minutes prior to the start time and refer to conference ID 3891009.
A live audio webcast of the call will also be available on the Investors section of Chimerix's website, www.chimerix.com. An archived webcast will be available on the Chimerix website approximately two hours after the event.
Chimerix's lead product candidate, brincidofovir, is a nucleotide analog that has antiviral activity against all five families of DNA viruses that affect humans, including the herpesviruses, adenoviruses, and poxviruses. Brincidofovir has a high barrier to resistance, no myelosuppression and a low risk of nephrotoxicity. Brincidofovir has received Fast Track designation from the FDA and Orphan Medicinal Product Designation from the European Commission for smallpox and has Orphan Drug Designation for smallpox.
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for patients with life threatening diseases. Brincidofovir (BCV, CMX001) uses Chimerix's proprietary lipid conjugate. For further information, please visit Chimerix's website, www.chimerix.com.
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include those relating to, among other things, Chimerix’s plans to complete a restructuring and the estimated impact on cash resources, Chimerix’s plans to pursue external opportunities to build its pipeline and the potential benefits of such a transaction, and the submission of marketing applications for BCV for the treatment of smallpox. Risks and uncertainties include whether the termination of oral and intravenous clinical trials of brincidofovir and the planned restructuring will have the intended impact of conserving cash resources, Chimerix’s ability to identify potential external opportunities and to complete or realize a benefit from any transaction that it pursues; whether Chimerix will be able to obtain marketing approval for brincidofovir for the treatment of smallpox; and additional risks set forth in the Company's filings with the Securities and Exchange Commission. These forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.
Stern Investor Relations
CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)
March 31, 2019
December 31, 2018
Cash and cash equivalents
Short-term investments, available-for-sale
Prepaid expenses and other current assets
Total current assets
Property and equipment, net of accumulated depreciation
Operating lease right-of-use assets
Other long-term assets
LIABILITIES AND STOCKHOLDERS' EQUITY
Total current liabilities
Preferred stock, $0.001 par value, 10,000,000 shares authorized at March 31, 2019 and December 31, 2018; no shares issued and outstanding as of March 31, 2019 and December 31, 2018
Common stock, $0.001 par value, 200,000,000 shares authorized at March 31, 2019 and December 31, 2018; 51,023,842 and 50,735,279 shares issued and outstanding as of March 31, 2019 and December 31, 2018, respectively
Additional paid-in capital
Accumulated other comprehensive gain (loss), net
Total stockholders’ equity
Total liabilities and stockholders’ equity
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except share and per share data)
Three Months Ended March 31,
Research and development
General and administrative
Total operating expenses
Loss from operations
Other (expense) income:
Unrealized loss on equity investment
Interest income and other, net
Other comprehensive loss:
Unrealized gain (loss) on debt investments, net
Per share information:
Net loss, basic and diluted
Weighted-average shares outstanding, basic and diluted